Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic Markers

Kandimalla, Raju; Tilborg, Angela A.G. van; Kompier, Lucie C.; Stumpel, Dominique J.P.M.; Stam, Ronald W.; Bangma, Chris H.; Zwarthoff, Ellen C.

doi:10.1016/j.eururo.2012.01.011

Cited by 95 publications

(73 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collectively these studies suggest that under certain circumstances TBX3 suppression may promote cancer progression. Furthermore, a study investigating the genome-wide methylation pattern of fresh-frozen bladder cancer tumour tissue revealed that TBX3 methylation is associated with the progression of non-muscle invasive human bladder tumours (Pta) to muscle-invasive tumours (MI) (78). The authors of this study also showed that TBX3 methylation was an independent predictor of bladder cancer progression and that it correlated with reduced progression-free survival.…”

Section: The Tumour Suppressor Role Of Tbx3supporting

confidence: 54%

“…They demonstrated that patients with low TBX3 methylation experienced significantly increased progressionfree survival and that, within 10 years of follow-up time, TBX3 was an independent prognostic marker of progression risk. Interestingly, both studies revealed that methylation of the TBX3 homologue, TBX2, was also linked to tumour progression of bladder cancer (78,79).…”

Section: The Tumour Suppressor Role Of Tbx3mentioning

confidence: 99%

See 1 more Smart Citation

The T-Box transcription factor 3 in development and cancer

Willmer

Cooper

Peres

et al. 2017

BST

View full text Add to dashboard Cite

Section: The Tumour Suppressor Role Of Tbx3supporting

confidence: 54%

Section: The Tumour Suppressor Role Of Tbx3mentioning

confidence: 99%

The T-Box transcription factor 3 in development and cancer

Willmer

Cooper

Peres

et al. 2017

BST

View full text Add to dashboard Cite

“…It has been reported that TBX2 is a specific genomic marker for late-stage ovarian cancers [12]. Similarly, TBX2 has also been recognized as prognostic markers in bladder cancer [13]. However, we know little about whether TBX2 was implicated in NSCLC.…”

Section: Discussionmentioning

confidence: 93%

High TBX2 expression predicts poor prognosis in non-small cell lung cancer

Zhang¹,

Guo²

2014

neo

View full text Add to dashboard Cite

Deregulated expression of T-box2 (TBX2) has been implicated in malignancies. However, the expression pattern and the role of TBX2 in non-small cell lung cancer (NSCLC) remain unclear. The aim of this study was to explore the clinical value of TBX2 in patients with NSCLC. We examined TBX2 expression in 40 NSCLC tissues and matched adjacent noncancerous tissues by quantitative RT-PCR (qRT-PCR) and Western blotting. Furthermore, the TBX2 protein expression was analyzed by immunohistochemistry in 416 NSCLC samples. Kaplan-Meier method and multivariate Cox regression model were used to evaluate the prognostic value of TBX2 expression in NSCLC for disease survival. The expression of TBX2 was significantly elevated in NSCLC tissues as compared with adjacent non-cancerous tissues (P<0.001). The high expression of TBX2 in NSCLC was significantly correlated with lymph node metastasis and tumor node metastasis (TNM) stage. Kaplan-Meier survival analysis revealed that high expression of TBX2 correlated with poor prognosis of NSCLC patients (P<0.01). Multivariate analysis showed that TBX2 expression was an independent prognostic marker for overall survival of NSCLC patients (HR=2.21, 95%CI=1.349-3.905, P=0.0015). Our results suggest that high TBX2 expression is associated with poor prognosis of NSCLC patients, and TBX2 may be a prognostic biomarker for NSCLC.

show abstract

“…Multivariate Cox proportional hazard analysis was used to estimate the independent prognostic effect of PCDH17 methylation, controlling for classic risk factors (tumour size, stage and grade). [17][18][19] Statistical analyses were carried out using SAS version 8.0 (SAS Institute, Cary, NC, USA). P-values <0.05 (twosided) were considered statistically significant.…”

Section: Statistical Analysesmentioning

confidence: 99%

Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer

Luo

Li²,

Gui

et al. 2013

J Int Med Res

View full text Add to dashboard Cite

Objective: To investigate the prognostic value of protocadherin 17 (PCDH17) promoter methylation in serum-derived DNA of patients with bladder cancer. Methods: DNA was isolated from serum of patients with bladder cancer and from age-and sexmatched controls. Methylation-specific polymerase chain reaction was used to examine the methylation status of the PCDH17 promoter. The correlations between methylation status and clinicopathological characteristics and overall survival were examined. Results: PCDH17 promoter methylation was detected in 79/151 (52.3%) of patients with bladder cancer, and none of the 43 control subjects. Methylation was significantly associated with larger tumour diameter (>3 cm), high grade (G 3 ) and advanced stage (T 2 -T 4 ). Patients with PCDH17 promoter methylation had significantly shorter overall survival than those with unmethylated PCDH17 promoter. Methylation was an independent predictor of overall survival. Conclusions: PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. The detection of PCDH17 promoter methylation in serum-derived DNA may be a convenient and noninvasive predictive biomarker in routine clinical practice.

show abstract

Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic Markers

Cited by 95 publications

References 36 publications

The T-Box transcription factor 3 in development and cancer

The T-Box transcription factor 3 in development and cancer

High TBX2 expression predicts poor prognosis in non-small cell lung cancer

Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer

Contact Info

Product

Resources

About